Precision medicine

From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. As the US National Cancer Research Month draws to a close, we asked experts from across the industry “What do you feel has been the […]

Not-for-profit medical research organisation LifeArc and techbio company PrecisionLife have agreed a strategic R&D collaboration to accelerate the discovery of targeted treatments for motor neurone disease (MND). MND is also known as amyotrophic lateral sclerosis (ALS) and Lou Gehrig’s disease. The collaboration will accelerate findings by PrecisionLife working with the Motor Neurone Disease Association and […]

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this latest episode, DDW’s Megan Thomas is in conversation with Dr Michael Pace, Global & Strategic Feasibility Expert at Rho.  Leveraging historical trial databases […]

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this latest episode, DDW’s Megan Thomas is in conversation with Dr Michael Pace, Global & Strategic Feasibility Expert at Rho.  Leveraging historical trial databases […]

AI drug discovery company MultiOmic Health has closed a £5 million ($6.2 million) seed funding extension round to build a precision therapeutics discovery platform for metabolic syndrome-related medical conditions. The round was led by London-based Hoxton Ventures, with participation from Ada Ventures, MMC Ventures and Verve Ventures. Since beginning operations in May 2021, MultiOmic has […]

Anthony Schmitt, PhD, Senior Vice President, Science at Arima Genomics, discusses the applications of 3D genomics in cancer research. Efforts to fulfil the promise of precision medicine, including the use of targeted cancer therapies, necessitate that patients be treated based on the specific genetic alterations that drive their individual cancers. It is now more common for […]

Oliver Schon, PhD, is VP Research & Development at BiVictriX Therapeutics, a UK-based emerging drug discovery and development company generating a pioneering first-in-class next-generation ADC anti-cancer therapeutics which exhibit superior selectivity towards cancer. Dr Schon is applying his broad expertise from lead discovery to manufacture in order to progress differentiated, safe and developable bi-specific therapeutic […]

From humble beginnings in the founder’s basement, UK-based Aptamer Group is now supplying its Optimer binders to clients across big pharma. DDW’s Diana Spencer caught up with co-founder and CEO Dr Arron Tolley. DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on […]

Genomics is driving a revolution in drug development and, in the long run, the state of public healthcare. Advances in sequencing are leading to scientific breakthroughs in preventative care, faster diagnoses, and proactive medical interventions. Jack Dix, Head of Healthcare Strategy and Consulting at Kainos, expands.  Genetic insights are also guiding healthcare closer to precision […]

DDW’s Diana Spencer reports on the recent Avacta Therapeutics Science Day, which explored the latest exciting developments in precision and targeted treatments for cancer and asked what advances the future might bring. The Avacta Therapeutics Science Day brought together senior company scientists and international oncology experts to provide an overview of the current development of […]